Again, this study highlights the potential therapeutic capability of GLP-1 as a neuroprotective agent, particularly through its anti-inflammatory mediatory ability
However, if STAT5b mediates both metabolic signaling and IGF-I production it still needs to be understood where the two pathways diverge, and why GH metabolic signaling is not blocked in the absence of insulin crosstalk
The peptide's ability to enhance HGF activity is key here, as HGF is known for its regenerative properties in neural tissues Neuroinflammation Reduction : The reduction of neuroinflammation by Dihexa is another crucial therapeutic aspect
Microdosing involves administering a much lower amount of GLP-1 medication, typically 10% to 25% of a standard starting dose, to capture therapeutic benefits without aggressive physical changes
While clinical trials provide controlled and statistically significant data, individual experiences can highlight nuances and variations that might not be evident in larger studies
#GLP1 #Mounjaro #Wegovy #Ozempic #Zepbound #PatientCentricCare #PatientExperience #CanadianInnovation #CanadianCompany